In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Higher numbers of insured leading to more treatment of hypertension, high cholesterol and diabetes.
The FDA has approved the first PCSK9 inhibitor to treat certain adults with high cholesterol.
An FDA advisory committee has recommended approval of alirocumab (Praluent, Regeneron) for treatment of hypercholesterolemia.
The PCSK9 inhibitor evolocumab appears to be safe and effective for reducing LDL cholesterol in older patients.
Review shows no changes for rheumatoid arthritis patients with tumor necrosis factor antagonist treatment.
Two studies show that PCSK9 inhibition lowered LDL cholesterol in heterozygous and homozygous familial hypercholesterolemia.
Long-term statin use among children with familial hypercholesterolemia is associated with normalization of carotid intima-media thickness progression.
Sanofi and Regeneron announced positive results from four phase 3 ODYSSEY trials of alirocumab in patients with hypercholesterolemia.
Amgen announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for evolocumab for the treatment of high cholesterol.
Cutting traditional risk factors could eliminate significant amount of cardiovascular disease
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis
- When Physicians Become Patients: Challenges in Seeking Health Care
- Statin Use and Cardiovascular Risk Perception Varies Among Races
- Impact of a Longer Work Week on Diabetes Incidence
- Relationship Between Estradiol Level and Mortality in Elderly Men